Posted on Leave a comment

Cannabinoids for Scleroderma

Two compounds that target the endocannabinoid system are currently in development to treat scleroderma – and they’re already in clinical trials. Pharmaceutical researchers have their sights set on developing a drug that bypasses CB1 while boosting CB2. Referred to as a “selective CB2 agonist,” such a compound would appear to have potential as a treatment for scleroderma.Original Article

Leave a Reply

Your email address will not be published. Required fields are marked *